AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pomerantz LLP Investigates Claims Against Ultragenyx Pharmaceutical Inc.
ByAinvest
Tuesday, Sep 2, 2025 10:05 am ET1min read
Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. alleging securities fraud or unlawful business practices. The investigation concerns a Phase 3 study of UX143 for osteogenesis imperfecta. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Pomerantz LLP, a leading firm in corporate, securities, and antitrust class litigation, has initiated an investigation on behalf of investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The investigation centers around allegations of securities fraud or unlawful business practices by Ultragenyx and certain of its officers and/or directors.The investigation was sparked by a press release issued by Ultragenyx and its development partner, Mereo BioPharma Group plc, on July 9, 2025. The release announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) was progressing toward a final analysis. The Data Monitoring Committee meeting advised that the final analysis would occur around the end of the year.
Following this announcement, Ultragenyx's stock price experienced a significant drop. On July 10, 2025, the stock fell by $10.41 per share, or 25.11%, closing at $31.04 per share.
Investors affected by this situation are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information about joining the class action.
Pomerantz LLP has a long-standing reputation for fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has recovered numerous multimillion-dollar damages awards on behalf of class members.
References:
[1] https://www.morningstar.com/news/globe-newswire/9519210/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc-rare
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc---rare-302538525.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet